{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire

  1. Asian Indians have been found to develop cardiovascular diseases at young age than Caucasians *

  2. Asian Indians have a unique pattern of dyslipidemia characterized by *

  3. South Asians manifest CVD at lower levels of total cholesterol compared with other ethnic groups *

  4. Considering the higher CV mortality in our country, do you feel threshold for various cholesterol levels to initiate treatment should be lower than western counterparts *

  5. Do you believe that elevated LDL Cholesterol is an important cause of coronary cause of coronary artery disease and ischemic stroke? *

  6. How many Patients do you encounter with Dyslipidemia in your daily practice? *

  7. Right down the % of patients having following risk factors along with dyslipidemia in your daily practice? *

    8. %

    %

    %

    %

    %
  8. Which Method do you use to stratify cardiovascular risk in your patients? *

  9. What is your choice of Statin for Primary Prevention ? Please mention the use in % *

    10. %

    %

    %
  10. Do you prescribe statin to all diabetic patients above 50 years with multiple risk factors, but not CHD *

  11. Which statin do you prefer for diabetic patients? *

  12. What is your preferred drug option for patients with LDL >160 mg /dL, TG 200-499 mg /dL, and HDL < 40mg/dL without CHD or CHD risk equivalent? *
    (Give order of preference in case of multiple options)
    13. Molecule /Drug Preference

  13. What LDL-C targets or Goals do you prefer for your patients of primary prevention? *

  14. If LDL-C goal is achieved do you also keep the non-HDL-C target? *

  15. Do you alter existing therapy to attain non-HDL-C goal in patients with LDL levels at Goal *

  16. If yes, then which is your preferred strategy to attain non-HDL-C goal in these patients *

  17. The combination of high levels of Lp(a) and homocysteine, and high prevalence of diabetes, metabolic syndrome, and Asian Indian dyslipidaemia— and the synergistic interaction among these risk factors—best explains the high prevalence of premature, severe, diffuse, multi-vessel malignant CAD among Indians globally ( Do you agree / Disagree) *

  18. In approximately what % of your patients do you recommend hs-CRP testing? *

  19. What is your choice of statin for secondary prevention? *

  20. The Key components of Anti-thrombotic therapy for ACS patients include *

  21. In your opinion fixed dose combinations of statin and anti-platelet drugs have the following advantage *

  22. Fixed dose combinations of statin and anti-platelet drugs improve patient compliance and adherence *

  23. In your ACS Patients; for how long do you prefer Statin + DAPT Combination *

  24. In your opinion, is Rosuvastatin and Clopidogrel combination therapy beneficial for more effective management of Cardiovascular disease ? *

  25. Do you agree that early intensive Rosuvastatin use in ACS patients if effective in improving 12-month Outcomes? *

  26. Patients with postoperative myocardial infarction receiving dual anti-platelet therapy in combination with statin therapy has improved survival rates of *

  27. Triple drug therapy with dual anti-platelet therapy and lipid lowering statin helps in *

  28. Triple fixed dose combination therapy of Aspirin, Clopidogrel and Rosuvastatin was the most preferred choice of physicians, for optimal management Post ACS Patient in Indian Setting *

  29. In Your opinion, usage pattern of Fixed dose combination of Rosuvastatin 10 mg + Clopidogrel 75 mg + Aspirin 75 mg dose once daily for 1-3 years is recommended for ACS patients *

  30. Combination of Clopidogrel with statin has synergistic effects on the clinical outcomes of patients with ACS *

  31. Benefits of antiplatelet agents and statin before surgery include *

  32. Do you agree that antiplatelet and statin therapy in the perioperative period is associated with improved 30 day mortality and improved 5 year survival? *

  33. Dual antiplatelet therapy and high intensity statins are the mainstay treatments for intracranial atherosclerosis *

  34. In your opinion, does Rosuvastatin Plus Clopidogrel therapy effectively improve cardiac function parameter LVEF and Decrease wall motion score index in elderly CHD patients ? *

  35. Statin’s antithrombotic effects are additive to those exerted by standard dose of Clopidogrel *

  36. Pleotropic effects of Statin, apart from cholesterol lowering actions include *

  37. Statins play a key role in nephroprotection and myocardial protection after contrast medium administration of during PCI *

  38. Commonly prescribed dosage of triple drug therapy of Rosuvastatin and dual antiplatelet therapy is *

  39. Rosuvastatin has no effect on inhibition of platelet aggregation exerted by Aspirin or Clopidogrel *

  40. Which of the following Statins according to you has higher capacity of LDL Cholesterol lowering? *

  41. IN ACS management, high dose of Rosuvastatin is superior compared with high dose of Atorvastatin for lipid modification in ACS with similar safety and tolerability *

  42. Absence of combined antiplatelet and statin therapy at discharge after postoperative MI is associated with higher late mortality *

  43. High dose of Rosuvastatin administration early on admission results in a significantly lower incidence of Contrast Induced Acute Kidney Injury *

  44. Antiplatelets and statins are effective in preventing future cardiovascular events in patients with CHD *

  45. Disparity in cardiovascular outcomes exists by race /ethnicity and gender *

  46. Do you think that statins and antiplatelet combination therapy is underused? *

  47. Do you think high levels if initial prescription have not translated into long term treatment of CHD *

  48. Adherence to medication, Post MI is higher than ACS *

  49. A fixed dose combination of pill containing Aspirin, a Statin, and > 1 BP loweing agent could help to optimize the prevention of CV disease *

  50. DAPT along with Statin reduces the risk of CV events *